Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cost burden of diffuse large B-cell lymphoma
R. Andrew Harkins, Sharvil Patel, Christopher R. Flowers
Expert Review of Pharmacoeconomics & Outcomes Research (2019) Vol. 19, Iss. 6, pp. 645-661
Open Access | Times Cited: 22

Showing 22 citing articles:

Harnessing Engineered Immune Cells and Bacteria as Drug Carriers for Cancer Immunotherapy
Jingwen Jiang, Yanjuan Huang, Zishan Zeng, et al.
ACS Nano (2023) Vol. 17, Iss. 2, pp. 843-884
Closed Access | Times Cited: 28
Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis
Jonathan S. Rink, Adam Yuh Lin, Kaylin M. McMahon, et al.
Journal of Biological Chemistry (2020) Vol. 296, pp. 100100-100100
Open Access | Times Cited: 42
Use of a universal targeting CAR T cell to simultaneously kill cancer cells and cancer-associated fibroblasts
Bo Huang, Suilan Zheng, Kasireddy Sudarshan, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Diffuse large B-cell lymphoma: examining evolving patterns in mortality, incidence, and demographics
Silpa Choday, Eric Tran, Miguel González
Clinical & Translational Oncology (2025)
Open Access
Population based registry study on large B-cell lymphoma mortality and morbidity in Finland
Anna Anttalainen, Liisa Ukkola‐Vuoti, Ville Vihervaara, et al.
Acta Oncologica (2025) Vol. 64, pp. 303-311
Open Access
Shorting of existing conditioning regimen for relapsed/refractory gastric diffuse large B-cell lymphoma transplant and studying its related outcomes: A first of its kind case report
Pankaj Dwivedi, Yasam Venkata Ramesh, Raj Nagarkar
Iraqi Journal of Hematology (2025)
Open Access
Cellular therapies: Day by day, all the way
Erden Atilla, Pelin Kılıç, Günhan Gürman
Transfusion and Apheresis Science (2018) Vol. 57, Iss. 2, pp. 187-196
Closed Access | Times Cited: 19
Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective
Bernhard Mörtl, Martin Dreyling, Christian Schmidt, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 22, Iss. 7, pp. 474-482
Closed Access | Times Cited: 8
FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges
Melissa Z. Ong, Sharon A. Kimberly, W K Lee, et al.
Current Pharmaceutical Biotechnology (2023) Vol. 25, Iss. 11, pp. 1377-1393
Closed Access | Times Cited: 3
ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma
Juan Pablo Alderuccio, Jeff P. Sharman
Blood Reviews (2022) Vol. 56, pp. 100967-100967
Open Access | Times Cited: 4
Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival
Rafael Cerón Maldonado, Adolfo Martínez Tovar, Christian Omar Ramos Peñafiel, et al.
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1583-1595
Open Access | Times Cited: 4
Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?
Omran Saifi, Mohamed A. Kharfan‐Dabaja, Youssef H. Zeidan, et al.
International Journal of Particle Therapy (2020) Vol. 7, Iss. 1, pp. 13-20
Open Access | Times Cited: 5
Cost of Disease Progression in Diffuse Large B-Cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
John M. Burke, Anthony Masaquel, Rongrong Wang, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 11, pp. e393-e404
Open Access | Times Cited: 1
Cost-effectiveness analysis of combining lenalidomide with R-CHOP for treating diffuse large B-cell lymphoma in China
Rongqi Li, Yuhan Zeng, Yizhang Chen, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram
Yu Guo, Jie Lian, Yao Chen, et al.
Hematology (2024) Vol. 30, Iss. 1
Open Access
Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
Bushra Kanwal
Cureus (2021)
Open Access | Times Cited: 3
Economic burden in non‐Hodgkin lymphoma survivors: The French Lymphoma Study Association SIMONAL cross‐sectional study
Virginie Nerich, Christophe Guyeux, M. Henry‐Amar, et al.
Cancer (2021) Vol. 128, Iss. 3, pp. 519-528
Open Access | Times Cited: 2
Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma
Julia Thornton Snider, Donna McMorrow, Xue Song, et al.
Clinical Therapeutics (2022) Vol. 44, Iss. 4, pp. 521-538
Open Access | Times Cited: 1
Factors Influencing Physician Discretion to Administer CNS Prophylaxis in Diffuse Large B Cell Lymphoma: A Single Institution Retrospective Study
Christopher Hino, Curtis Lacy, Joel Brothers, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 10, pp. 764-771
Closed Access
Targeting Scavenger Receptor Type B1 In Cholesterol-Addicted Lymphomas Abolishes Glutathione Peroxidase 4 and Results in Ferroptosis
Jonathan S. Rink, Adam Yuh Lin, Kaylin M. McMahon, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access
How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?
R. Andrew Harkins, Christopher R. Flowers
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 61, Iss. 14, pp. 3283-3286
Open Access
SINGLE-CENTER EXPERIENCE IN RELAPSED/REFRACTORY NON-HODGKIN’S LYMPHOMA (RELAPS/REFRAKTER NON HODGKİN LENFOMALARDA TEK MERKEZ DENEYİMİ)
Hatice Terzi, Kübra ORAL, Hüseyin Yılmaz, et al.
Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi (2022)
Open Access
Page 1

Scroll to top